Risk Factors for VOD in 249 Patients Grafted Between January 1990 and June 1995, Univariate Analysis, Logistic Regression
| Factor . | VOD . | P . | |
|---|---|---|---|
| Yes . | No . | ||
| Recipient sex female | 14/24 (58%) | 79/225 (35%) | .03 |
| Recipient age >17 years | 21/24 (88%) | 146/225 (65%) | .04 |
| Hematologic malignancies | 21/24 (88%) | 186/225 (83%) | .52 |
| Advanced disease* | 11/24 (46%) | 83/225 (37%) | .35 |
| Recipient CMV seropositive before BMT | 18/24 (75%) | 148/225 (66%) | .37 |
| Recipient positive herpes virus serology (3-4)† | 22/24 (92%) | 164/225 (73%) | .08 |
| GVHD prophylaxis with combination therapy‡ | 24/24 (100%) | 210/225 (93%) | .08 |
| Busulphan | 10/24 (42%) | 63/225 (28%) | .17 |
| IVIG prophylaxis | 12/24 (50%) | 99/225 (44%) | .37 |
| Liver disease before BMT | 4/24 (17%) | 20/225 (19%) | .25 |
| Previous abdominal irradiation | 3/24 (12%) | 8/225 (4%) | .06 |
| Infection 1 week before BMT | 1/24 (4%) | 8/225 (4%) | .88 |
| Fever 1 week before BMT | 12/24 (5%) | 86/225 (38%) | .26 |
| Unrelated transplant | 6/24 (25%) | 66/225 (30%) | .66 |
| HLA mismatch | 4/24 (17%) | 7/225 (3%) | .015 |
| ALAT >0.7 μkat/L before BMT | 9/24 (38%) | 84/225 (37%) | .99 |
| Bilirubin >26 μmol/L before BMT | 3/24 (12%) | 3/225 (1%) | <.001 |
| Prophylaxis or treatment started within 1 week before BMT | |||
| Trimethoprim-sulphamethoxazole | 18/24 (75%) | 193/225 (86%) | .17 |
| Acyklovir | 13/24 (54%) | 121/225 (54%) | .97 |
| Vancomycin | 3/24 (12%) | 21/225 (9%) | .62 |
| Amphotericin | 2/24 (8%) | 27/225 (12%) | .60 |
| Norethisterone | 13/24 (54%) | 42/225 (19%) | <.001 |
| Omeprazol | 4/24 (17%) | 30/225 (13%) | .65 |
| Factor . | VOD . | P . | |
|---|---|---|---|
| Yes . | No . | ||
| Recipient sex female | 14/24 (58%) | 79/225 (35%) | .03 |
| Recipient age >17 years | 21/24 (88%) | 146/225 (65%) | .04 |
| Hematologic malignancies | 21/24 (88%) | 186/225 (83%) | .52 |
| Advanced disease* | 11/24 (46%) | 83/225 (37%) | .35 |
| Recipient CMV seropositive before BMT | 18/24 (75%) | 148/225 (66%) | .37 |
| Recipient positive herpes virus serology (3-4)† | 22/24 (92%) | 164/225 (73%) | .08 |
| GVHD prophylaxis with combination therapy‡ | 24/24 (100%) | 210/225 (93%) | .08 |
| Busulphan | 10/24 (42%) | 63/225 (28%) | .17 |
| IVIG prophylaxis | 12/24 (50%) | 99/225 (44%) | .37 |
| Liver disease before BMT | 4/24 (17%) | 20/225 (19%) | .25 |
| Previous abdominal irradiation | 3/24 (12%) | 8/225 (4%) | .06 |
| Infection 1 week before BMT | 1/24 (4%) | 8/225 (4%) | .88 |
| Fever 1 week before BMT | 12/24 (5%) | 86/225 (38%) | .26 |
| Unrelated transplant | 6/24 (25%) | 66/225 (30%) | .66 |
| HLA mismatch | 4/24 (17%) | 7/225 (3%) | .015 |
| ALAT >0.7 μkat/L before BMT | 9/24 (38%) | 84/225 (37%) | .99 |
| Bilirubin >26 μmol/L before BMT | 3/24 (12%) | 3/225 (1%) | <.001 |
| Prophylaxis or treatment started within 1 week before BMT | |||
| Trimethoprim-sulphamethoxazole | 18/24 (75%) | 193/225 (86%) | .17 |
| Acyklovir | 13/24 (54%) | 121/225 (54%) | .97 |
| Vancomycin | 3/24 (12%) | 21/225 (9%) | .62 |
| Amphotericin | 2/24 (8%) | 27/225 (12%) | .60 |
| Norethisterone | 13/24 (54%) | 42/225 (19%) | <.001 |
| Omeprazol | 4/24 (17%) | 30/225 (13%) | .65 |